Page 1694 - Hall et al (2015) Principles of Critical Care-McGraw-Hill

References 5

132. Ahmari S, Bunch T, Chandra A, et al. Prevalence, pathophysiol- 149. Fishman J, Rubin R. Infection in organ-transplant recipients.
ogy, and clinical significance of post-hear transplant atrial fibril- N Engl J Med. 1998;338(24):1741-1751.
lation and atrial flutter. J Heart Lung Transplant. 2006;25:53-60. 150. Mañez R, Breinig M, Linden P, et al. Factors associated with
133. Pavri B, O’Nunain S, Newell J, Ruskin J, William G. Prevalence the development of post-transplant lymphoproliferative disease
and prognostic significance of atrial arrhythmias after ortho- (PTLD) in Epstein-Barr virus (EBV)-seronegative adult liver
topic cardiac transplantation. J Am Coll Cardiol. 1995;25(7): transplant recipients. Transpl Int. 1994;7(suppl 1):S235-S237.
1673-1680. 151. Walker R, Marshall W, Strickler J, et al. Pretransplantation
134. Dasari T, Pavlovic-Surjancev B, Patel N, et al. Incidence, risk assessment of the risk of lymphoproliferative disorder. Clin
factors, and clinical outcomes of atrial fibrillation and atrial flut- Infect Dis. 1995;20(5):1346-1353.
ter after heart transplantation. Am J Cardiol. 2010;106:737-741. 152. Tzakis A. Cytomegalovirus prophylaxis with ganciclovir and
135. Hosenpud J, Bennett L, Keck B, Boucek M, Novick R. The cytomegalovirus immune globulin in liver and intestinal trans-
Registry of the International Society for Heart and Lung plantation. Transpl Infect Dis. 2001;3(suppl 2):35-39.
Transplantation: eighteenth official report—2001. J Heart Lung 153. Fishman J. Infection in solid-organ transplant recipients. N Engl
Transplant. 2001;20:805-815. J Med. 2007;357:2601-2614.
136. Billingham M. Diagnosis of cardiac rejection by endomyocar- 154. Palmer S, Limaye A, Banks M, et al. Extended valganciclovir
dial biopsy. J Heart Lung Transplant. 1982;1:25. prophylaxis to prevent cytomegalovirus after lung transplanta-
137. Reitz B, Gaudiani V, Hunt S, et al. Diagnosis and treatment of tion. Ann Intern Med. 2010;152:761-769.
allograft rejection in heart-lung transplant recipients. J Thorac 155. Arcasoy S, Kotloff R. Lung transplantation. N Engl J Med.
Cardiovasc Surg. 1983;85:354. 1999;340(14):1081-1091.
138. Bilchick KC, Henrikson CA, Skojec D, Kasper EK, Blumenthal 156. Maurer J, Tullis D, Grossman R, Vellend H, Winton T, Patterson
RS. Treatment of hyperlipidemia in cardiac transplant recipi- G. Infectious complications following isolated lung transplanta-
ents. Am Heart J. 2004;148(2):200-210. tion. Chest. 1992;101(4):1056-1059.
139. Eisen H, Tuzcu E, Dorent R, et al. Everolimus for the prevention 157. Husain S, Paterson D, Studer S, et al. Voriconazole prophylaxis
of allograft rejection and vasculopathy in cardiac-transplant in lung transplant recipients. Am J Transplant. 2006;6:3008-
recipients. N Engl J Med. 2003;349(9):847-858. 3016.
140. Keogh A, Richardson M, Ruygrok P, et al. Sirolimus in de novo 158. Singh N, Husain S. Invasive aspergillosis in solid organ trans-
heart transplant recipients reduces acute rejection and prevents plant recipients. Am J Transplant. 2009;9(4):S180-S191.
coronary artery disease at 2 years: a randomized clinical trial.
Circulation. 2004;110(17):2694. 159. Singh N, Paterson D. Aspergillus infections in transplant recipi-
ents. Clin Microbiol Rev. 2005;18:44-69.
141. Schroeder J, Gao S, Alderman E, et al. A preliminary study of
diltiazem in the prevention of coronary artery disease in heart- 160. Herbrecht R, Denning D, Patterson T. Voriconazole versus
transplant recipients. N Engl J Med. 1993;328(3):164-170. amphotericin B for primary therapy of invasive aspergillosis.
N Engl J Med. 2002;347:408-415.
142. Costanzo M, Dipchand A, Starling R, et al. The International
Society of Heart and Lung Transplantation: guidelines for the 161. Walsh T, Anaissie E, Denning D. Treatment of aspergillosis:
care of heart transplant recipients. J Heart Lung Transplant. clinical practice guidelines of the Infectious Diseases Society of
2010;29:914-956. America. Clin Infect Dis. 2008;46:327-360.
143. Villacian J, Paya C. Prevention of infections in solid organ trans- 162. Husain S, Singh N. Burkholderia cepacia infection and lung
plant recipients. Transpl Infect Dis. 1999;1:50. transplantation. Semin Respir Infect. 2002;17(4):284-290.
144. Targeted tuberculin testing and treatment of latent tuberculosis 163. Charman S, Sharples L, McNeil K, Wallwork J. Assessment of
infection. Official statement of the American Thoracic Society survival benefit after lung transplantation by patient diagnosis.
was adopted by the ATS Board of Directors. Am J Respir Crit J Heart Lung Transplant. 2002;21(2):226-232.
Care Med. 1999;161:S221. 164. Egan T, Detterbeck F, Mill M, et al. Long-term results of lung
145. Kusne S, Shapiro R, Fung J. Prevention and treatment of cyto- transplantation for cystic fibrosis. Eur J Cardiothorac Surg.
megalovirus infection in organ transplant recipients. Transpl 2002;22(4):602-609.
Infect Dis. 1999;1(3):187-203. 165. Cruciani M, Mengoli C, Malena M, Bosco O, Serpelloni G,
146. Peggs K, Preiser W, Kottaridis P, et al. Extended routine poly- Grossi P. Antifungal prophylaxis in liver transplant patients: a
merase chain reaction surveillance and pre-emptive antiviral systematic review and meta-analysis. Liver Transpl. 2006;12(5):
therapy for cytomegalovirus after allogeneic transplantation. 850-858.
Br J Haematol. 2000;111(3):782-790. 166. Pappas P, Silveira F. Candida in solid organ transplant recipi-
147. Rubin R. Cytomegalovirus in solid organ transplantation. ents. Am J Transplant. 2009;9(4):S173-S179.
Transpl Infect Dis. 2001;3(suppl 2):1-5. 167. Dajani A, Taubert K, Wilson W, et al. Prevention of bacte-
148. Rubin RH, Wolfson JS, Cosimi AB, Tolkoff-Rubin NE. Infection rial endocarditis. Recommendations by the American Heart
in the renal transplant recipient. Am J Med. 1981;70(2):405-411. Association. JAMA. 1997;277:1794.

Section10-O-Ref.indd 5 1/21/2015 11:30:10 AM